Sentence examples for difference in the utility from inspiring English sources

Similarly, using the ESH/ESC definition of LVH, there was no difference in the utility of NT-proBNP in identifying patients with LVH AUCC 0.64).

The difference in the utility estimates between severe and very severe COPD was approximately three times larger than the difference between moderate and severe COPD.

Also, contrary to the findings in this study, she found that there was no difference in the utility found between anterior and posterior teeth.

Another possible limitation is that the minimum clinically significant difference in the utility of two health interventions is generally situated around 0.030 QALYs [ 49, 50] and the gains in QALYs observed in each patient evaluated with Cardio inCode®, in comparison with the standard method, were 0.0256 QALYs for REGICOR and 0.0166 QALYs for Framingham.

Furthermore, to aid robust cost-effectiveness estimations, the costs associated with usual care and RM interventions need to be reported in detail (including the costs of HF treatment pathways) and QoL needs to be reported with observations at specific time points in order to estimate the difference in the utility of the patients between the RM and usual care groups.

A gender (and racial) difference in the utility of insulin-based fasting and OGTT-based models has recently been described by Pisprasert et al., who found that gender as well as race, had a significant effect on explaining the predictability of clamp-measured glucose disposal rates (GDR) [ 46].

Rosenbloom [16] stated that a small difference in the utilities of alternatives may not be appropriate to conclude that one alternative is superior to the other.

Further, the differences in stage, tumour size, and lymph node status observed here may reflect differences in the utility of screening approaches to detect different histologic types of cancer.

When differences in the utility values between corresponding health states of different treatments were reduced by 25% by increasing the base case utility values of MPH, the incremental cost per QALY gained became €4864343 and €3068585 (see Figure 2).

As in the base case, both analyses showed significant differences in the utility values between groups.

In BLISS-76, the EQ-5D VAS score significantly improved with belimumab 1 mg/kg at week 52, without significant between-treatment differences in the utility index or component questions.